Brief Description
Study to assess the efficacy, pharmacokinetics (PK), safety and tolerability of iptacopan in pediatric patients with primary IgAN
Estimated Enrollment
2
Estimated End Date
June 2030
Trial is for people with
Pediatric patients with IgAN
Study Goal
The purpose of this single-arm, multicenter, Phase III study is to assess the efficacy, PK and safety of iptacopan in pediatric ...
What is involved for the patient?
Participants in Cohort 1 (12 to < 18 years old) will receive iptacopan at the dose of 200 mg twice per day. Participants in Cohort 2 ...
About the drug or intervention
Iptacopan is a complement inhibitor, specifically targeting factor B in the complement pathway, which is involved in the body's immune ...